- Study: Higher levels of sleep aid melatonin may reduce prostate cancer risk
- Study: Daily aspirin use may reduce risk of ovarian cancer by 20%
- Giant Eagle acquires Rx21 Specialty Pharmacy, enabling enhanced hepatitis C/organ transplant services
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Novartis acquires CoStim Pharmaceuticals
SEATTLE — The Food and Drug Administration has approved biotech company Dendreon’s expansion of manufacturing capacity for an immunotherapy treatment for prostate cancer, Dendreon said Thursday.
The company said it would be able to increase the ability of Provenge (sipuleucel-T) manufactured at its plant in New Jersey by increasing the number of workstations to produce it from 12 to 48.
The treatment is designed to induce an immune response against prostatic acid phosphatase, an antigen present in most prostate cancers.
The company said it expects to have around 225 infusion centers prepared to treat their first patient by the end of the second quarter, and 500 by the end of the year.